Eli Lilly's obesity drug Zepbound gains approval to treat sleep apnea [USA TODAY]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: USA TODAY
Zepbound is the first medication approved to treat patients with obstructive sleep apnea, said Sally Seymour, the FDA's director of the division of pulmonology, allergy and critical care. The FDA said the popular weight-loss drug should be combined with a reduced-calorie diet and increased physical activity. What is apnea? Obstructive sleep apnea happens when a person's upper airway becomes blocked and pauses breathing during sleep. The condition happens more often in people who are overweight or have obesity. Symptoms can include snoring, fatigue, daytime sleepiness and disrupted sleep. Sleep apnea can significantly increase health risks , even the risk of death, so doctors strongly recommend people address it. But standard therapy with breathing devices known as CPAPs are not hugely popular with patients. Studies suggest that one-third to half of apnea patients either quit using a continuous positive airway pressure machine or never fill their prescription for it. One man
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves Alhemo® injection as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B with inhibitors [Yahoo! Finance]Yahoo! Finance
- Why Viking Therapeutics Tumbled by More Than 10% This Week [Yahoo! Finance]Yahoo! Finance
- Stock market today: Dow, S&P 500, Nasdaq rebound on fresh inflation data to cap volatile week [Yahoo! Finance Canada]Yahoo! Finance Canada
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk shares tumble as data on weight-loss drug trial disappoints [Financial Times (FT.com) (UK)]Financial Times
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website